Quick Order

HER2 / ErbB2 / CD340 Antibody (FITC), Rabbit MAb

  • HER2 / ErbB2 / CD340 Antibody (FITC), Rabbit MAb, Flow cytometric
  • HER2 / ErbB2 / CD340 Antibody (FITC), Rabbit MAb, Flow cytometric
DatasheetReviewsRelated ProductsProtocols
Human ErbB2/HER2 Antibody Product Information
Immunogen:Recombinant Human ErbB2 protein (Catalog#10004-H08H)
Clone ID:511
Ig Type:Rabbit IgG
Concentration:10 μl/Test, 0.1 mg/ml
Endotoxin:
Formulation:Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Preparation:This antibody was obtained from a rabbit immunized with purified, recombinant Human ErbB2 / HER2 extracellular domain (rh ErbB2; Catalog#10004-H08H; NP_004439.2; Met 1-Thr 652) and conjugated with FITC under optimum conditions, the unreacted FITC was removed .
Human ErbB2/HER2 Antibody FC Application Image
HER2 / ErbB2 / CD340 Antibody (FITC), Rabbit MAb, Flow cytometric
[Click to enlarge image]
Caption:
Flow cytometric analysis of anti-ErbB2 on HeLa cells. HeLa cells were detached using 1X trypsin, washed, then stained with FITC Rabbit anti-Human ErbB2.
HER2 / ErbB2 / CD340 Antibody (FITC), Rabbit MAb, Flow cytometric
[Click to enlarge image]
Caption:
Flow cytometric analysis of anti-ErbB2 on SK-BR3 cells. SK-BR3 cells were detached using 1X trypsin, washed, then stained with FITC Rabbit anti-Human ErbB2.
Other ErbB2/HER2 Antibody Products
HER2/ERBB2 Background

Epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Human HER2/ERBB2 References
  • Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.
  • Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"